Comparative Pharmacology
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus ZYRTEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOCETIRIZINE DIHYDROCHLORIDE versus ZYRTEC.
LEVOCETIRIZINE DIHYDROCHLORIDE vs ZYRTEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levocetirizine is a selective antagonist of peripheral histamine H1 receptors, blocking histamine-induced allergic responses by inhibiting H1 receptor activation in the gastrointestinal tract, blood vessels, and respiratory tract.
Selective histamine H1-receptor antagonist; inhibits histamine release from mast cells and basophils.
5 mg orally once daily in the evening.
5-10 mg orally once daily; maximum 10 mg/day.
None Documented
None Documented
Terminal elimination half-life: 7-11 hours in adults. Clinically, this supports once-daily dosing; may be prolonged in renal impairment (creatinine clearance <30 mL/min).
Terminal elimination half-life is approximately 8-11 hours in healthy adults, prolonged in renal impairment (e.g., up to 20 hours in moderate renal failure).
Renal: 85% as unchanged drug (70%) and metabolites (15%); fecal: 13%; biliary: minimal (<2%).
Cetirizine is primarily excreted unchanged in urine (approximately 70% renal elimination) and feces (about 10%).
Category A/B
Category C
Antihistamine
Antihistamine